As of 29 September 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of bevacizumab [25 mg/mL concentrate for solution for intravenous (IV) infusion] in combination with a platinum-taxane doublet chemotherapy, specifically cisplatin [1 mg/mL solution for IV infusion] or carboplatin [10 mg/mL solution for IV infusion; lyophilized powder continue reading : HTA Council Preliminary Recommendation on bevacizumab [25 mg/mL concentrate for solution for intravenous (IV) infusion] in combination with a platinum-taxane doublet chemotherapy, specifically cisplatin [1 mg/mL solution for IV infusion] or carboplatin [10 mg/mL solution for IV infusion; lyophilized powder for injection in 150 mg and 450 mg vial] + paclitaxel [6 mg/mL solution for IV infusion] for the treatment of metastatic, persistent or recurrent cervical cancer
HTA Council Preliminary Recommendation on alendronic acid (as sodium alendronate) 70 mg effervescent tablet for the treatment of postmenopausal osteoporosis
As of 24 September 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of alendronic acid (as sodium alendronate) 70 mg effervescent tablet for the treatment of postmenopausal osteoporosis. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 24 continue reading : HTA Council Preliminary Recommendation on alendronic acid (as sodium alendronate) 70 mg effervescent tablet for the treatment of postmenopausal osteoporosis